MDSpire - Summary
Clinical Guidelines

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Share

Emerging treatment strategies for advanced melanoma, especially extracutaneous types, were outlined during a JADPRO Live 2025 session led by Dr. Alexandra Haugh and Ms. Krista M. Rubin at Mass General Hospital. The session emphasized the significance of immune-based therapies such as ImmTAC therapies and TIL therapy, which are gaining traction in treating conditions like mucosal and uveal melanoma. These approaches reflect the need for targeted therapies tailored to specific mutant profiles and molecular prognostication for better patient outcomes.

Original Source(s)

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

  • by Alexandra Haugh, MD, Krista M. Rubin, MS, FNP-BC

  • March 30, 2026

Related Content

New Frontiers in Neuroendocrine Tumors: Enhancing Diagnosis, Treatment, and Patient Outcomes

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

These results come from the pilot phase of the phase III ADARNAT randomized international clinical trial, which is investigating whether axillary radiotherapy has a lower risk of lymphedema than axill...

Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk

“The results of our study show that tailoring the extent of radiotherapy according to how well the chemotherapy has worked to treat cancer in the lymph nodes leads to very low and reassuring recurrenc...